Patents by Inventor Christopher John Bond

Christopher John Bond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20230279101
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 7, 2023
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 11512128
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 29, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20220288203
    Abstract: The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.
    Type: Application
    Filed: August 13, 2021
    Publication date: September 15, 2022
    Inventors: Kelley Marshall MCNAGNY, Calvin D. ROSKELLEY, Michael R. HUGHES, Diana CANALS HERNAEZ, Klas Ola BLIXT, John Stephen BABCOOK, Christopher John BOND, Ismael SAMUDIO, Jan Peter BERGQVIST, Katherine Grace MACDONALD, Anna VON ROSSUM, Bradley John HEDBERG, Pamela Megan DEAN
  • Anti-podocalyxin antibodies and methods of using the same
    Patent number: 11090383
    Abstract: The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 17, 2021
    Inventors: Kelly Marshall McNagny, Calvin D. Roskelley, Michael R. Hughes, Diana Canals Hernaez, Klas Ola Blixt, John Stephen Babcook, Christopher John Bond, Ismael Samudio, Jan Peter Bergqvist, Katherine Grace MacDonald, Anna Von Rossum, Bradley John Hedberg, Pamela Megan Dean
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20210061903
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 4, 2021
    Inventors: AUSTIN L. GURNEY, Aaron Ken Sato, Christopher John Bond
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 10730940
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 4, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • VEGF/DLL4 BINDING AGENTS AND USES THEREOF
    Publication number: 20190062424
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: August 29, 2018
    Publication date: February 28, 2019
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20180305449
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 25, 2018
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20180296673
    Abstract: The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 18, 2018
    Inventors: Kelly Marshall MCNAGNY, Calvin D. ROSKELLEY, Michael R. HUGHES, Diana Canals HERNAEZ, Klas Ola BLIXT, John Stephen BABCOOK, Christopher John BOND, Ismael SAMUDIO, Jan Peter BERGQVIST, Katherine Grace MACDONALD, Anna VON ROSSUM, Bradley John HEDBERG
  • Modified immunoglobulin molecules that specifically bind human VEGF and DLL4
    Patent number: 9879084
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 30, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20170183406
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: January 9, 2017
    Publication date: June 29, 2017
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Christopher John Bond
  • Polynucleotides encoding VEGF/DLL4 binding agents
    Patent number: 9574009
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: February 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Polynucleotides Encoding VEGF/DLL4 Binding Agents
    Publication number: 20160362499
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 15, 2016
    Inventors: Austin L. GURNEY, Aaron Ken SATO, Christopher John BOND
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20160319034
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: November 3, 2016
    Inventors: Austin L. GURNEY, Ming-Hong XIE, Christopher John BOND
  • VEGF binding antibodies
    Patent number: 9376488
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: June 28, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20160137744
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: September 14, 2015
    Publication date: May 19, 2016
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
  • MET-binding agents and uses thereof
    Patent number: 9168300
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 27, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Ming-Hong Xie, Christopher John Bond
  • VEGF/DLL4 Binding Agents and Uses Thereof
    Publication number: 20150098949
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 9, 2015
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, CHRISTOPHER JOHN BOND
  • VEGF/DLL4 binding agents and uses thereof
    Patent number: 8858941
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: October 14, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20140286951
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond